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Schizophrenia, basic
ISS-01. The putative function of NR-1 in the
pathophysiology of schizophrenia
ISS-01.01 DISC1, GRIK4 and NPAS3 genes contribute to the risk of
developing schizophrenia, bipolar disorder and depression
D. Blackwood. University of Edinburgh, Division of Psychiatry, United Kingdom
Depression is common in patients with schizophrenia and it is well established
from family studies that rates of depression are increased among relatives of
probands with schizophrenia. Family linkage studies in both schizophrenia and
bipolar disorder have identified several chromosomal regions likely to contain
risk genes for psychiatric illness and some regions overlap in schizophrenia
and bipolar families suggesting common susceptibility loci. Candidate gene
association studies also suggest that some genes contribute to both affective and
non affective psychoses. Significant association and linkage have been reported
with two of the most studied candidates, Neuregulin 1 (NR-1) and Disrupted
in Schizophrenia 1 (DISC1) in schizophrenia, schizoaffective disorders, bipolar
disorder and depression. However the regions associated with affective and
non affective illness differ suggesting that various mutations in one gene may
underlie the phenotypic differences. This is supported by an association study of
DISC1 using several European cohorts of patients with bipolar disorder and
schizophrenia (Hennah 2008). SNPs at two different loci showed significant
association with bipolar illness and interaction of these two markers with a third
SNP was also detected. These results suggest allelic and locus heterogeneity
may underlie the diversity of psychiatric phenotypes. We have examined a third
candidate gene for a role in both schizophrenia and affective disorders, GRIK4
a kainate ionotropic glutamate receptor mapped to chromosome 11q23 (Pickard
2006). This gene is disrupted by a chromosomal breakpoint in a patient with
schizophrenia and low IQ. A case/control study show a significant association
of GRIK4 with both schizophrenia and bipolar disorder and the association with
schizophrenia is with markers at different domains of the gene than those showing
association with bipolar disorder. The role of these three candidate genes in
the pathogenesis of psychoses is not known but we can speculate that they
may be involved in fundamental processes of neurodevelopment or neurogenesis
increasing risk of mental disorders and the clinical phenotype as expressed in
the adult will be the result of modulation by environmental factors and other
genetic modifiers.
Hennah W (2008). Molecular Psychiatry (in press).
Pickard BS (2006) Molecular Psychiatry 11: 847–857.
ISS-01.02 Immunohistochemical evidence for impaired neuregulin-1
signaling in the prefrontal cortex in schizophrenia and in
unipolar depression
B. Bogerts1, I. Bertram1, H. Dobrowolny1, H.-G. Bernstein1. 1Medizinische
Universität Magdeburg, Psychiatrie und Psychotherapie, Germany
Objective: Neuregulin-1 proteins play roles in neuronal migration, differentiation
and survival of oligodendrocytes. The NRG-1 gene codes for at least 15 different
isoforms. At least four different haplotypes of the NRG-1 gene may be associated
with schizophrenia. An abnormal expression pattern of NRG-1 mRNA was
found in the prefrontal cortex of schizophrenic patients. Here we investigated
in post-mortem brains the expression of the two NRG-1 isoforms a and b in
schizophrenia.
Methods: NRG-1a was visualized by immunohistochemistry whole brain
serial sections of 22 schizophrenics, 12 patients with affective disorders and
22 matched controls, NRG-1b in brains of 7 schizophrenics, 6 patients with
affective disorders and 8 matched controls. NRG-1a immunoreactive material
was detected with a polyclonal antiserum against human heregulin/neuregulin
(antibody Ab-3 from Neomarkers), for NRG-1b we used the polyclonal antibody
Ab-2 from Neomarkers. The number of profiles of NRG-1a immunoreactive
neurons per hemisphere was counted using a computer assisted analysis system.
NRG-1b immunopositive cells in den DLPFC and ACC were counted by using
a light microscope.
Results: Normal anatomical distribution showed for NRG-1a only few im-
munopositive interneurons located in the prefrontal gray and white matter,
whereas NRG-1b revealed a widespread immunoreactivity in pyramidal cells and
interneurons in the gray matter of DLPFC and anterior cingulate cortex (ACC).
In schizophrenia stereologic analysis revealed a significant reduction of NRG-1a
cells in the white as well as in the gray cortical matter. In patients with unipolar
depression the density of NRG-1a immunoreactive neurons was also significantly
reduced in the prefrontal gray matter. In contrast to the 1a-isoform, NRG-1b
immunopositive interneurons and pyramidal cells in DLPFC and ACC were
significantly increased in schizophrenics in comparison to controls. Interneurons
of the DLPFC differed significantly between cases of affective disorders and
schizophrenics.
Conclusion: The diminished expression of NRG-1a in interstitial white matter
neurons supports a neurodevelopmental component to schizophrenia (disturbed
migration). With regard to NRG-1b we assume that the increase of the im-
munopositive neurons in schizophrenics leads to a hypofunction of NMDA-
receptors via enhanced binding of this NRG-1 isoform to its receptor, ErbB4
(Hahn et al. 2006). However the increased expression of NRG-1b could also be
due to the chronic administration of antipsychotics.
(1) Hahn et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA
receptor hypofunction in schizophrenia. Nat Med 2006 Jul; 12(7): 824−8.
(2) Bernstein HG, et al. Brain Res Bull 2006 15; 69(5): 546−59.
(3) Bertram I, et al. Ann NY Acad Sci 2007 Jan; 1096: 147−56.
ISS-01.04 Testing the functional impact of at-risk haplotypes for
schizophrenia with neurobiological measures
M. Wagner. University of Bonn, Psychiatry and Psychotherapy, Germany
Neuregulin 1 has been identified as a potential susceptibility gene for schiz-
ophrenia. As with other candidate genes, initial findings have been difficult
to replicate, because across studies different haplotypes were associated with
the disease (Munafo et al., Schizophrenia Bulletin, 2008). SNP8NRG221533
was the single most significant variant in the original Icelandic haplotype and
was included in several replication studies since then. Because neuregulin is
implicated in neuronal development and synaptic transmission, we examined the
impact of SNP8NRG221533 on neuropsychological, volumetric and functional
measures of the brain in schizophrenia. In a study of 100 patients with first-
episode of schizophrenia, SNP8_221533 was significantly associated with several
measures of executive function (Trail making test B, Digit Symbol Substitution,
Word fluency). A subsample of these first episode patients also underwent fMRI
with an n-back paradigm. Patients without the at-risk allele at SNP8_221533
showed stronger activations in the left parahippocampal gyrus, the superior
frontal gyrus, lateral temporal lobe, precuneus and the right anterior cingulate.
In a separate study, we found that hippocampal brain volumes in schizophrenic
patients and also in their relatives were affected by the core Icelandic haplotype
comprising the same NRG1 SNP (Gruber et al., J. Psychiat Res., in press).
Thus, while the association of specific SNPs and haplotpyes of the NRG1 gene
with schizophrenia may appear less convincing than some years ago, NRG1
variants appear to affect brain functional and structural measures in patients and
their relatives, corroborating that frequent polymorphisms (and possibly also rare
mutations) in this gene impact on intermediate phenotypes of schizophrenia.
ISS-01.05 Environmental modulation of phenotype in neuregulin 1
mutants
T. Karl1, A. Boucher2, B. Dean3, X.-F. Huang4, J. Arnold2, P. Schofield5.
1Garvan Inst. of Medical Research, Schizophrenia Research Inst., Sydney, NSW,
Australia; 2University of Sydney, Dept. of Pharmacology, Sydney, NSW, Aus-
tralia; 3Mental Health Research Inst., Rebecca L. Cooper Research Laboratory,
Melbournce, VIC, Australia; 4University of Wollongong, School of Health Sci-
ences, Wollongong, NSW, Australia; 5Prince of Wales Medicine Research Inst.,
Neuroscience, Sydney, NSW, Australia
Objective: Schizophrenia with its multi-factorial aetiology has a concordance
rate of 30−50% for monozygotic twins highlighting the fact that neither envi-
ronment nor genetics alone are sufficient to cause schizophrenia but a combined
action is likely. There is strong evidence that the human neuregulin 1 (NRG1)
gene is a schizophrenia candidate gene and mice mutant for transmembrane do-
main (TM) Nrg1 exhibit a marked schizophrenia-related behavioural phenotype.
ISS-02. Dopamine and Clinical Depression: New Findings 69
A variety of environmental risk factors have been proposed as contributing to
the development of schizophrenia, including stress and chronic use of drugs of
abuse. We hypothesise that subjects with a pre-existing genetic vulnerability for
schizophrenia may be more susceptible to these environmental factors.
Methods: Using a multi-factorial animal model strategy, we investigated the
neurobehavioural phenotype of male heterozygous TM Nrg1 mutant mice (Nrg1
HET) and their wild type-like (WT) littermates, which (i) were kept in different
housing conditions [i.e. standard vs. enriched housing], or (ii) were treated
acutely with drugs of abuse [i.e. amphetamine (AMP; 5 mg/kg body weight)
or the psychoactive constituent of cannabis, delta-9-tetrahydrocannabinol (THC;
5/10 mg/kg body weight)]. All mice were tested in a variety of tasks for locomo-
tion, exploration, anxiety, working memory and sensorimotor gating. Expression
analyses were performed for a variety of receptor systems. Furthermore, c-Fos
expression analysis determined neuronal correlates for the behavioural effects of
acute THC.
Results: Nrg1 mutants were more susceptible to the stimulation of motor
activity and exploration induced by environmental enrichment and its anxiolytic-
like effects. Acute AMP treatment induced similar locomotor hyperactivity and
disruptions of PPI as well as working memory performance in mutant and WT
mice. However, Nrg1 HETs were more sensitive to the locomotor suppressant
actions of THC and expressed a greater THC-induced enhancement in %PPI
compared to WT mice. Mutants were also more susceptible to the anxiogenic
effects of THC. Nrg1 hypomorphs expressed greater basal c-Fos levels in the
shell of the nucleus accumbens and the ventrolateral septum (LSV) and a global
increase in cortical serotonin 2A receptors. THC selectively increased c-Fos
expression in the LSV, the central nucleus of the amygdala and the paraventricular
nucleus of Nrg1 HETs.
Conclusion: These data suggest an interaction between Nrg1 and environ-
mental factors. It appears that variation in the Nrg1 gene alters the sensitivity
to the neurobehavioural effects of environmental enrichment and cannabinoids.
Importantly, our study adds evidence to face and construct validity of this genetic
animal model for schizophrenia.
Affective Disorders, basic
ISS-02. Dopamine and Clinical Depression: New
Findings
ISS-02.01 Dopamine and the regulation of mood and motivational
states in humans
M. Leyton. McGill University, Dept. of Psychiatry, Montreal, Quebec, Canada
Objective: Ascending midbrain dopamine neurons project widely, innervating
most motor and limbic forebrain regions. Activation of this system has been
proposed to influence psychomotor activity, motivational states, and responses to
rewards and punishments. Although this research has occurred primarily within
the context of studies of substance abuse, Parkinson’s disease, and ADHD, recent
findings have rekindled interest in dopamine’s potential role in mood disorders.
In the following brief review, the author summarizes the history of these ideas
and considers their possible relevance for understanding depression.
Methods: A systematic review of the literature using PubMed, and the
keywords, depression, mood, dopamine, reward, stress, and motivation.
Results: Consistent with the animal literature, functional neuroimaging studies
in humans indicate that striatal dopamine release can be elicited by a wide range
of affectively relevant events, including drugs of abuse, drug-related stimuli,
food and food cues, motivationally engaging video games, and psychological
stressors. The behavioral significance of these changes, though, remains a
subject of debate; however, studies of the effects of experimental reductions in
dopamine transmission and naturally occurring brain lesions suggest that the most
consistent effects are changes in (i) the initiation of movement, (ii) the ability
of positively valenced stimuli to elicit and sustain focused attention, and (iii) a
sense of well-being and optimistic affect. Unadulterated pleasure, in comparison,
is largely unaffected.
Conclusion: The overall pattern of findings suggests that dopamine strongly
influences sustained interest and approach, modestly influences positive emo-
tions, but affects pleasure only tenuously, if at all. Together these effects
could influence susceptibility to a wide range of clinically relevant symptoms,
particularly psychomotor retardation, loss of interest, and a general sense of
dissatisfied pessimistic apathy; the inability to experience pleasure (anhedonia),
though, likely reflects disturbances to other transmitter systems.
ISS-02.02 Functional connectivity of dopamine, serotonin and
norepinephrine neurons as revealed by lesion studies and
antidepressant drugs
P. Blier1, O. Chernoloz1, N. Katz1, F. Chenu1, M. El Mansari1, E. Dremencov1.
1University of Ottawa, Inst. of Mental Health Research, Canada
Objective: It is well established that dopamine neurons have anatomical connec-
tions with serotonin (5-HT) and norepinephrine (NE) neurons. The importance
of the functional connectivity of these reciprocal interactions had been suggested
in the past from a variety of studies. However, there was scarce knowledge on
the effects of sustained administration of various types of antidepressant drugs
on the activity of dopamine neurons, and on the actions of dopaminergic agents
effective in the treatment of depression on the activity of 5-HT and NE neurons.
Methods: In vivo electrophysiological recordings of dopamine, 5-HT, and NE
neurons were carried in the brain of anesthetized rats after acute, subacute and
prolonged administration of antidepressants.
Results: Sustained administration of the D2-like agonist pramipexole and
of the potent NE/dopamine reuptake inhibitor nomifensine, both effective in
depression, produced a transient inhibition of ventral tegmental area dopamine
neurons, and a desensitization of the cell body D2-like autoreceptors. In contrast,
they produced an enhancement of the firing rate of 5-HT neurons after 14 days
of administration. The monoamine oxidase inhibitors phenelzine and clorgyline
produced an inhibition of the firing rate of dopamine neurons which was mediated
in large part by enhanced 5-HT3 receptor activation. The selective 5-HT reuptake
inhibitor escitalopram produced a sustained inhibition of the firing of dopamine
neurons through the activation of 5-HT2C receptors.
Conclusion: These results document the fact that various classes of antide-
pressants all have profound effects of the activity of the dopamine neurons
giving rise to limbic and/or cortical projections. On the other hand, drugs with
dopaminergic properties can also influence other monoaminergic neurons. These
results provide a framework to perhaps understand treatment-resistant depression
in the perspective that to obtain an optimal response, some negative feedback
actions may have to be compensated for, or prevented.
ISS-02.03 Animal models of depression
A. Sulcova1, J. Pistovcakova1. 1Masaryk University, Pharmacology, Brno, Czech
Republic
Objective: To establish an animal behavioural model of depression an attention
has to be paid to behavioural changes that can be monitored objectively and
are reversed by the same treatment that is effective in clinics. The most
recognized animal behavioural models of depression in historical sequences are:
(a) Bilateral Olfactory Bulbectomy in rodents, (b) Mother-Infant Separation in
monkeys, (b) Learned Helplessness in dogs and rats (inescapable electric shocks),
(c) Forced Swim Test in rodents, (d) Chronic Mild Stress in rodents, (e) Drug-
withdrawal-induced anhedonia (f) Tail Suspension Test in mice, (g) Psychosocial
stress in rodents (Resident-Intruder test; agonistic behaviour). The results re-
ceived in potential antidepressant-like activity testing of selected drugs in rodent
models of (a) olfactory bulbectomy, and (b) social stress in repeatedly defeated
mice on paired agonistic interactions will be presented.
Methods: The bilateral ablation of the olfactory bulbs was performed by
aspiration in the anaesthetized rats as described by Leonard and Tuite [1981]. The
sham operated rats underwent the identical anaesthetic and drilling procedures
as olfactory bulbectomized (OB) animals, but their bulbs were left intact.
Experiments were carried out 3 weeks after the surgery. The characteristic
locomotor hyperactivity in the open-field test showed by OB rats was measured
in the open field (Acti-track infra-red beam based system, Panlab, s. l., Spain).
Results: (a) At the doses used none of drugs tested for their potential
antidepressant-like effects (e.g. felbamate, tiagabine, sertindole, amisulpride)
changed locomotor behaviour of sham-operated rats, however they inhibited
locomotor hyperactivity in the open field test in OB rats. (b) Compared to
control individuals the group-housed mice repeatedly defeated on interaction
with aggressive singly-housed male mouse exhibit significantly higher depression
of ambulation in the open field test. This was normalized by clinically proven
(e.g. citalopram, valproate) as well as potential antidepressants (e.g. felbamate,
rimonabant).
Conclusion: In conclusion, it is believed that drug testing in both in results
presented models could predict their beneficial effect on depression.
The work was supported by the research project MSM0021622404.
